Acute lymphoblastic leukemia (ALL) is a type of leukemia—a cancer of the bone marrow and blood.
Better Survival Rates for ALL
Studies have shown that the first treatment you receive for cancer is by far the most important. On average, leukemia patients who begin their treatment at Seattle Cancer Care Alliance (SCCA) have better survival rates than those who started treatment elsewhere. Our patients diagnosed with ALL receive expertly targeted, comprehensive care from a team of specialists who focus almost exclusively on treating this disease.
Access to Clinical Studies
SCCA, with its founding organizations Fred Hutchinson Cancer Research Center and UW Medicine, is a world leader in leukemia research and was formed, in part, to bring promising new treatments to patients faster. For people with ALL, this means more treatment options than you might find elsewhere, including the chance to participate in a clinical study for ALL.
Our researchers pioneered one of the most effective leukemia treatments, bone marrow transplantation, more than 50 years ago and continue to refine it today—for example, developing transplant options for people who have not found a matched donor. We are also advancing other key leukemia treatments, including improved chemotherapy and immunotherapy.
Excellent Transplant Results
Depending on the specifics of your leukemia, you may have several treatment options. One option—a bone marrow transplant—has transformed leukemia and related cancers, once thought incurable, into highly treatable diseases with survival rates as high as 80 percent. If your condition requires a bone marrow transplant, you should know that the Fred Hutchinson Bone Marrow Transplant Program at SCCA is one of 15 centers whose patients achieved higher-than-expected survival rates, according to a recent multi-year study by the Center for International Blood and Marrow Transplant Research (CIBMTR). We’ve performed more bone marrow transplants than any other institution in the world.